When was the $2.0 billion repurchase program authorized and when does it expire?

The Board of Directors approved the program in March 2026, and it expires on March 9, 2027. This is a 12-month authorization window that provides flexibility for execution timing.

How much of the $2.0 billion authorization has been executed so far?

As of June 30, 2026, the company had completed or largely completed two accelerated share repurchase agreements totaling approximately $1.5 billion, leaving $500 million remaining available through the March 2027 expiration date.

What is an accelerated share repurchase agreement and how did United Therapeutics use it here?

An ASR is an agreement with a bank to immediately repurchase a large block of shares, with final pricing and settlement occurring over time. United Therapeutics used ASRs to execute $1.5 billion of its $2.0 billion program, repurchasing 2,759,343 total shares, with settlements occurring in March/June 2026 and August 2026.

How did the company fund these repurchases?

United Therapeutics funded the ASR agreements by selling securities from its marketable investments portfolio. This reduced marketable investments and contributed to lower interest income in Q2 2026 ($31.5 million) versus Q2 2025 ($51.3 million).

What was the impact on share count and earnings per share?

The repurchases reduced basic share count from 45.1 million (Q2 2025) to 42.6 million (Q2 2025), a reduction of approximately 2.5 million shares. Despite a 2% decline in revenues, diluted EPS increased 13% due to lower share count, demonstrating the accretive effect of the buyback.

Why might United Therapeutics have pursued this repurchase program now?

The company cited potential regulatory approvals for ralinepag tablets and Nebulized Tyvaso in 2027 as 'transformative, multi-billion-dollar catalysts.' The timing reflects a strategic capital allocation decision to return excess cash via buybacks while maintaining $3.8 billion in liquid investments for R&D and potential M&A related to its organ-manufacturing pipeline.

UTHR 8-K Filed 2026-08-05 New authorization

United Therapeutics authorizes $2B share repurchase program

Board approved buyback in March 2026; company already completed two accelerated share repurchase agreements totaling ~$1.5B

Authorization$2.0B

Remaining$500M

MechanismAccelerated Share Repurchase

What the filing says

United Therapeutics Corporation announced in its second-quarter 2026 earnings filing that its Board of Directors approved a share repurchase program authorizing up to $2.0 billion in aggregate repurchases of common stock, effective March 9, 2026, and expiring March 9, 2027. The company simultaneously entered into two accelerated share repurchase (ASR) agreements with Citibank, N.A. in March 2026 to repurchase approximately $1.5 billion of common stock under the program.

During Q2 2026, the company received 378,936 shares upon first settlement of one ASR agreement, and a second ASR agreement settled in August 2026 with an additional 215,948 shares received. In total, United Therapeutics repurchased 2,759,343 shares under the 2026 ASR agreements, of which 2,543,395 were held as treasury stock as of June 30, 2026.

As of June 30, 2026, $500 million remained available under the $2.0 billion authorization for purchases through March 9, 2027. The company funded the ASR agreements through the sale of securities from its marketable investments portfolio, which contributed to a year-over-year decline in interest income from $51.3 million in Q2 2025 to $31.5 million in Q2 2026.

In March 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0 billion in aggregate repurchases of our common stock, which expires on March 9, 2027. In March 2026, we also entered into the 2026 ASR agreements with Citibank, N.A. to repurchase approximately $1.5 billion of our common stock. — UNITED THERAPEUTICS Corp 8-K filing · View on SEC EDGAR →

What this means

The $2.0 billion authorization represents a material capital return program for United Therapeutics, representing roughly 15% of the company's $13.5 billion market capitalization (based on ~42.6 million basic shares outstanding and the implied stock price context). The company executed $1.5 billion of the authorization immediately via ASR agreements, leaving $500 million unexercised through March 2027. The repurchase reduced the company's basic share count from approximately 45.1 million shares (Q2 2025) to 42.6 million shares (Q2 2025), contributing to a 14% increase in diluted EPS despite a 2% decline in revenues. The use of accelerated buybacks funded by liquidating marketable securities reflects a capital allocation decision to return cash while maintaining operational flexibility.

Frequently asked questions

When was the $2.0 billion repurchase program authorized and when does it expire?: The Board of Directors approved the program in March 2026, and it expires on March 9, 2027. This is a 12-month authorization window that provides flexibility for execution timing.
How much of the $2.0 billion authorization has been executed so far?: As of June 30, 2026, the company had completed or largely completed two accelerated share repurchase agreements totaling approximately $1.5 billion, leaving $500 million remaining available through the March 2027 expiration date.
What is an accelerated share repurchase agreement and how did United Therapeutics use it here?: An ASR is an agreement with a bank to immediately repurchase a large block of shares, with final pricing and settlement occurring over time. United Therapeutics used ASRs to execute $1.5 billion of its $2.0 billion program, repurchasing 2,759,343 total shares, with settlements occurring in March/June 2026 and August 2026.
How did the company fund these repurchases?: United Therapeutics funded the ASR agreements by selling securities from its marketable investments portfolio. This reduced marketable investments and contributed to lower interest income in Q2 2026 ($31.5 million) versus Q2 2025 ($51.3 million).
What was the impact on share count and earnings per share?: The repurchases reduced basic share count from 45.1 million (Q2 2025) to 42.6 million (Q2 2025), a reduction of approximately 2.5 million shares. Despite a 2% decline in revenues, diluted EPS increased 13% due to lower share count, demonstrating the accretive effect of the buyback.
Why might United Therapeutics have pursued this repurchase program now?: The company cited potential regulatory approvals for ralinepag tablets and Nebulized Tyvaso in 2027 as 'transformative, multi-billion-dollar catalysts.' The timing reflects a strategic capital allocation decision to return excess cash via buybacks while maintaining $3.8 billion in liquid investments for R&D and potential M&A related to its organ-manufacturing pipeline.

authorization asr mega-cap rare-disease execution 2026

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.